Soidjon Khodjaev, MD
Cardiovascular Disease · Rochester, NYNPI 1629313572
Payments from drug & device makers
Across 352 payments — averaging $40.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Actelion Pharmaceuticals US, Inc.$5K
- Cvrx, Inc.$2K
- Abiomed$2K
- Abbott$633
- Novartis$584
- AstraZeneca$549
- plus $3K from 24 others
What the payments were for
- Consulting fees$3,27523%
- Travel & lodging$2,86220%
- Food & beverage$7,91555%
- Education$3372%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Actelion Pharmaceuticals US, Inc. | 139 | $5,483 |
| Cvrx, Inc. | 16 | $2,419 |
| Abiomed | 11 | $1,922 |
| Abbott | 19 | $633 |
| Novartis | 32 | $584 |
| AstraZeneca | 31 | $549 |
| Merck | 15 | $371 |
| E.r. Squibb & Sons, L.L.C. | 5 | $265 |
| Johnson & Johnson | 11 | $231 |
| Boehringer Ingelheim | 9 | $194 |
| Inari Medical, Inc. | 1 | $153 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 10 | $144 |
| Livanova USA, Inc. | 1 | $143 |
| Pfizer | 7 | $137 |
| Impulse Dynamics (USA) Inc. | 2 | $123 |
| Akcea Therapeutics, Inc. | 2 | $120 |
| Lexicon Pharmaceuticals, Inc. | 5 | $110 |
| Alnylam Pharmaceuticals Inc. | 5 | $107 |
| Edwards Lifesciences | 3 | $99 |
| Novo Nordisk | 5 | $96 |
| Scpharmaceuticals Inc. | 4 | $83 |
| Amgen | 4 | $79 |
| Bayer | 3 | $67 |
| Kiniksa Pharmaceuticals, Ltd. | 3 | $60 |
| Liquidia Technologies, Inc. | 2 | $60 |
| United Therapeutics Corporation | 2 | $42 |
| Kestra Medical Technology Services, Inc. | 2 | $40 |
| Atricure, Inc. | 1 | $30 |
| Chiesi USA, Inc. | 1 | $23 |
| GSK | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UPTRAVI$3,373
- Barostim Neo System$2,084
- Impella$1,609
- OPSUMIT$297
- FLOWTRIEVER CATHETER, S$153
- CT THROMBECTOMY SYSTEM KIT$153
- LifeSPARC$143
- CAMZYOS$122
- HeartMate 3 Left Ventricular Assist Device$116
- OPTIMIZER SMART SYSTEM$107
How this compares
$14,389 in reported general payments places this provider in the 80th percentile of 2,302 cardiovascular disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 108 | $134,633 |
| RemodulinTreprostinil Sodium | 11 | $79,761 |
| JardianceEmpagliflozin | 52 | $65,571 |
| OzempicSemaglutide | 26 | $34,507 |
| EliquisApixaban | 28 | $28,177 |
| FarxigaDapagliflozin Propanediol | 21 | $26,118 |
| Metoprolol Succinate | 173 | $2,807 |
| Torsemide | 81 | $2,228 |
| Midodrine Hcl | 21 | $1,595 |
| Spironolactone | 179 | $1,055 |
| Furosemide | 58 | $323 |
| Carvedilol | 41 | $265 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 14 | $153 |
| Atorvastatin Calcium | 16 | $144 |
| Hydralazine Hcl | 15 | $103 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $584 | $134,633108 claims |
| United Therapeutics CorporationRemodulin | $42 | $79,76111 claims |
| Boehringer IngelheimJardiance | $194 | $65,57152 claims |
| Novo NordiskOzempic | $96 | $34,50726 claims |
| PfizerEliquis | $137 | $28,17728 claims |
| AstraZenecaFarxiga | $549 | $26,11821 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,302 cardiovascular disease providers in New York.
Other cardiovascular disease in Rochester
- James EichelbergerRochester$332K
- James MinNew York$41.1M
- Robert RosensonNew York$6.9M
- Roxana MehranNew York$6.4M
- Roger HajjarNew York$5.2M
- Philippe GenereuxNew York$4.4M
- Vijay IyerAmherst$4.3M
- Gregg StoneNew York$3.7M
- Szilard VorosStony Brook$3.7M
- Valentin FusterNew York$2.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.